The biotech is focusing on neurological situations with a brand new drug candidate, developed with the assistance of researchers at FutureNeuro.
Neumirna Therapeutics, a Danish RNA-focused biotech firm has raised €20m in a Collection A funding to develop therapies for epilepsy and different neurological situations. The funding was co-led by Angelini Ventures and Invivo Companions, and noticed participation from Neumirna’s seed investor, Innovestor’s Life Science Fund.
The beginning-up mentioned that the funding will allow it to start medical trials for NMT.001, its therapeutic candidate for drug-resistant epilepsy (DRE).
FutureNeuro, the Analysis Eire Centre for Translational Mind Science, has been a key associate within the preclinical growth of this drug candidate, with early-stage analysis constructing on the Centre’s foundational work in RNA therapies.
In keeping with Neumirna, preclinical research for NMT.001 confirmed “unprecedented efficacy” in animal fashions of DRE, highlighting its potential to “considerably enhance affected person outcomes and high quality of life”.
Furthermore, the corporate’s drug discovery platform additionally permits the event of RNA therapies that sort out different situations comparable to Parkinson’s illness.
“This funding milestone is a testomony to the groundbreaking potential of our RNA-based platform and our lead growth candidate, NMT.001,” mentioned Prof Janine Erler, the CEO of Neumirna.
“This funding is important to carry NMT.001 to medical trials and advance our pipeline.”
Prof David Henshall, FutureNeuro’s director and a professor of molecular physiology and neuroscience at RCSI College of Drugs and Well being Sciences, mentioned: “The invention of the hyperlink between the microRNA gene and epilepsy originated right here at RCSI, and thru the FutureNeuro Centre, we partnered with Neumirna to establish probably the most promising drug candidate.
“This achievement highlights the vital significance of working carefully with trade to translate early-stage analysis into tangible therapies that may make an actual distinction for sufferers.”
“By leveraging microRNA-targeted medicine to handle the underlying causes of illnesses like epilepsy and Parkinson’s illness, Neumirna is breaking new floor within the area,” mentioned Thomas Thestrup, a senior principal at Angelini Ventures.
“With our robust deal with mind issues and a dedication to advancing progressive therapies for epilepsy, we’re excited to collaborate with Neumirna’s administration workforce on this journey to develop transformative options for sufferers worldwide.”
SiliconRepublic.com spoke to Prof Mark Cunningham, a FutureNeuro investigator final yr, who established, for the primary time in Eire, the capability to conduct stay human mind tissue research from sufferers with refractory epilepsy.
Furthermore, 2024 was an enormous yr for the popularity of the significance of RNA, with scientists Victor Ambros and Gary Ruvkun profitable the Nobel Prize in Physiology or Drugs for his or her discovery of microRNAs within the Eighties.
Don’t miss out on the information you could succeed. Join the Day by day Transient, Silicon Republic’s digest of need-to-know sci-tech information.
